CL2020003197A1 - Compuestos de bencenosulfonamida y su uso como agentes terapéuticos. - Google Patents

Compuestos de bencenosulfonamida y su uso como agentes terapéuticos.

Info

Publication number
CL2020003197A1
CL2020003197A1 CL2020003197A CL2020003197A CL2020003197A1 CL 2020003197 A1 CL2020003197 A1 CL 2020003197A1 CL 2020003197 A CL2020003197 A CL 2020003197A CL 2020003197 A CL2020003197 A CL 2020003197A CL 2020003197 A1 CL2020003197 A1 CL 2020003197A1
Authority
CL
Chile
Prior art keywords
therapeutic agents
benzenesulfonamide compounds
benzenesulfonamide
compounds
seizures
Prior art date
Application number
CL2020003197A
Other languages
English (en)
Inventor
Alla Yurevna Zenova
Michael Scott Wilson
Thilo Focken
Kristen Nicole Burford
Verner Alexander Lofstrand
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CL2020003197A1 publication Critical patent/CL2020003197A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Esta invención está dirigida a compuestos de bencensulfonamida, como estereoisómeros,<br /> enantiómeros, tautómeros de los mismos o mezclas de los mismos; o sus sales, solvatos o<br /> profármacos farmacéuticamente aceptables, para el tratamiento de enfermedades o afecciones<br /> asociadas con canales de sodio dependientes de voltaje, tales como epilepsia y/o trastornos de<br /> ataques epilépticos.
CL2020003197A 2018-06-13 2020-12-09 Compuestos de bencenosulfonamida y su uso como agentes terapéuticos. CL2020003197A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862684436P 2018-06-13 2018-06-13

Publications (1)

Publication Number Publication Date
CL2020003197A1 true CL2020003197A1 (es) 2021-04-30

Family

ID=67138087

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003197A CL2020003197A1 (es) 2018-06-13 2020-12-09 Compuestos de bencenosulfonamida y su uso como agentes terapéuticos.

Country Status (23)

Country Link
US (2) US10745392B2 (es)
EP (1) EP3807281A1 (es)
JP (2) JP7371029B2 (es)
KR (1) KR20210019507A (es)
CN (1) CN112262142B (es)
AU (1) AU2019285184B2 (es)
BR (1) BR112020024729A2 (es)
CA (1) CA3103600A1 (es)
CL (1) CL2020003197A1 (es)
CR (1) CR20200613A (es)
EA (1) EA202092719A1 (es)
EC (1) ECSP20079861A (es)
IL (1) IL278949B1 (es)
JO (1) JOP20200304A1 (es)
MA (1) MA52888A (es)
MX (1) MX2020013317A (es)
NI (1) NI202000098A (es)
PE (1) PE20211389A1 (es)
PH (1) PH12020552111A1 (es)
SA (1) SA520420768B1 (es)
SG (1) SG11202011862PA (es)
UA (1) UA127024C2 (es)
WO (1) WO2019241533A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201809702SA (en) * 2016-05-20 2018-12-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
SG10201912372XA (en) 2016-12-09 2020-02-27 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
PE20211389A1 (es) * 2018-06-13 2021-07-27 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos
PE20211066A1 (es) 2018-08-31 2021-06-09 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
CN1184957C (zh) 1997-05-07 2005-01-19 盖伦(化学制品)有限公司 用于给药睾酮和睾酮前体的阴道内给药装置
WO2000042003A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
DE19907385A1 (de) 1999-02-20 2000-08-24 Boehringer Ingelheim Pharma Neue substituierte 3-Phenoxy- und 3-Phenylalkyloxy-2-phenyl-propylamine
CA2378381A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
JP2005162726A (ja) 2003-01-24 2005-06-23 Tanabe Seiyaku Co Ltd ピラゾロピリミジン化合物およびその製法
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2005005421A1 (en) 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
JP2007501804A (ja) 2003-08-08 2007-02-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
JP2008524244A (ja) 2004-12-17 2008-07-10 タケダ サン ディエゴ インコーポレイテッド 水酸化ステロイド脱水素酵素阻害剤
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
JP2009510144A (ja) 2005-10-06 2009-03-12 サノフィ−アベンティス ４−オキシ−ｎ−［１，３，４］−チアジアゾール−２−イル−ベンゼンスルホンアミド類、それらの製造方法及びそれらの医薬品としての使用
CA2633653A1 (en) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
CN101506165B (zh) 2006-08-15 2012-07-04 霍夫曼-拉罗奇有限公司 苯基、吡啶和喹啉衍生物
RU2474582C2 (ru) 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
JP5463285B2 (ja) 2007-07-13 2014-04-09 アイカジェン， インコーポレイテッド ナトリウムチャネル阻害物質
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2009099177A1 (ja) 2008-02-06 2009-08-13 Taisho Pharmaceutical Co., Ltd. アミノイミダゾール誘導体
CA2727340A1 (en) 2008-06-25 2009-12-30 Daiichi Sankyo Company, Limited Carboxylic acid compound
US7846954B2 (en) 2008-07-01 2010-12-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
US20110294853A1 (en) 2008-09-12 2011-12-01 Benjamin Pelcman Bis Aromatic Compounds for Use in the Treatment of Inflammation
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
NZ606751A (en) 2010-08-20 2015-04-24 Hutchison Medipharma Ltd Pyrrolopyrimidine compounds and uses thereof
WO2013025883A1 (en) 2011-08-17 2013-02-21 Amgen Inc. Heteroaryl sodium channel inhibitors
AU2012328561A1 (en) 2011-10-28 2014-04-17 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
BR112014010368A2 (pt) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaril éter sulfonamidas e seu uso como agentes terapêuticos
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
MX2014014234A (es) 2012-05-22 2015-05-07 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor.
ES2828503T3 (es) 2012-10-15 2021-05-26 Dae Woong Pharma Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos
US9624208B2 (en) 2012-10-26 2017-04-18 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
CN104869992A (zh) 2012-10-26 2015-08-26 默沙东公司 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
CN105705501B (zh) 2013-09-09 2019-04-19 百时美施贵宝公司 RORγ调节剂
MY181928A (en) 2013-09-10 2021-01-14 Chromocell Corp Sodium channel modulators for the treatment of pain and diabetes
CA2931732A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
JP6337124B2 (ja) 2013-12-23 2018-06-06 パーデュー、ファーマ、リミテッド、パートナーシップ インダゾール及びその使用
WO2016177340A1 (zh) 2015-05-05 2016-11-10 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
US10519147B2 (en) 2015-12-18 2019-12-31 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
WO2017165204A1 (en) 2016-03-22 2017-09-28 Merck Sharp & Dohme Corp. N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels
SG11201809702SA (en) 2016-05-20 2018-12-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
US10836758B2 (en) 2016-10-27 2020-11-17 Bristol-Myers Squibb Company Acyl sulfonamide NaV1.7 inhibitors
WO2018093694A1 (en) 2016-11-17 2018-05-24 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
SG10201912372XA (en) * 2016-12-09 2020-02-27 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
PE20211389A1 (es) 2018-06-13 2021-07-27 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos
JP7383012B2 (ja) 2018-08-31 2023-11-17 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用
PE20211066A1 (es) 2018-08-31 2021-06-09 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos

Also Published As

Publication number Publication date
PE20211389A1 (es) 2021-07-27
EA202092719A1 (ru) 2021-03-16
JP7371029B2 (ja) 2023-10-30
JP2021528387A (ja) 2021-10-21
US10745392B2 (en) 2020-08-18
ECSP20079861A (es) 2021-03-31
WO2019241533A1 (en) 2019-12-19
CN112262142A (zh) 2021-01-22
PH12020552111A1 (en) 2021-08-02
US11325902B2 (en) 2022-05-10
MX2020013317A (es) 2021-04-13
MA52888A (fr) 2021-04-21
IL278949B1 (en) 2024-04-01
IL278949A (en) 2021-01-31
US20200361927A1 (en) 2020-11-19
KR20210019507A (ko) 2021-02-22
SG11202011862PA (en) 2020-12-30
JP2023138672A (ja) 2023-10-02
EP3807281A1 (en) 2021-04-21
CR20200613A (es) 2021-06-10
AU2019285184B2 (en) 2023-11-16
CA3103600A1 (en) 2019-12-19
CN112262142B (zh) 2023-11-14
JOP20200304A1 (ar) 2020-11-25
NI202000098A (es) 2021-05-28
AU2019285184A1 (en) 2021-01-28
UA127024C2 (uk) 2023-03-15
BR112020024729A2 (pt) 2021-03-23
SA520420768B1 (ar) 2022-08-30
US20190382398A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
NI202100013A (es) Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapéuticos.
CO2019005552A2 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
CL2020003197A1 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos.
CO2018012485A2 (es) Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos
MX2020004405A (es) Compuestos biciclicos en puente como moduladores del receptor farnesoide x.
CO2017012545A2 (es) Sulfonas tricíclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rorγ)
UY36630A (es) Moduladores tricíclicos de la señalización por tnf
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
CO2021010611A2 (es) Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
ECSP19072975A (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos
EA201991128A1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
DOP2020000234A (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
CO2021007442A2 (es) Compuesto de 1,3,4-oxadiazolona y fármaco
CL2021002144A1 (es) Compuesto heterociclo pentacíclico.